摘要
目的:探讨卵巢肿瘤风险预测模型(ROMA)在卵巢肿瘤诊断中的应用价值。方法:回顾性分析因卵巢肿瘤住院接受手术的良性肿瘤患者41例,恶性肿瘤患者42例及正常受试者40例,用ELISA法检测血清中HE4与CA125水平,计算ROMA值以评估患卵巢肿瘤的风险性。结果:卵巢肿瘤组患者血清HE4、CA125水平及ROMA值高于对照组和良性肿瘤组,差异有统计学意义(P<0.01)。良性肿瘤组CA125水平值高于对照组值,差异有统计学意义(P<0.01);而HE4水平及ROMA与对照组比较差异无统计学意义(P>0.05)。以HE4≥150pmol/L,CA125≥35U/ml作为阳性界限,则HE4、CA125及ROMA值敏感度分别为83.33%,69.04%85.71%;特异度分别为95.12%,78.0%,95.12%。CA125ROC曲线下面积(AUC)为0.676;HE4ROC曲线下面积(AUC)为0.749;ROMA ROC曲线下面积(AUC)为0.814,与CA125、HE4比较差异有统计学意义(P<0.05)。结论:在卵巢肿瘤诊断中,单项检测HE4的临床价值优于CA125。对于单项HE4、CA125检测而言,HE4、CA125联合应用计算ROMA值具有更好的诊断卵巢恶性肿瘤的临床价值。
Objective：To investigate the ovarian cancer risk prediction model（ROMA）in the diagnosis of ovarian cancer.Method：Serum HE4 and CA125levels were detected by ELISA in 42 ovarian cancer patients,41 ovarian benign cyst patients and 40 normal subjects.ROMA was evaluated by HE4 and CA125levels.Result：Ovarian cancer serum HE4,CA125 level and ROMA value were higher than those in control group and benign tumor group,and the difference was statistically significant（P〈0.01）.The level of CA125 in benign tumor group was higher than that in the control group,and the difference was statistically significant（P〈0.01）,while no statistical significance in HE4 levels and ROMA（P〉0.05）.If the cut-off values（positive limits）of HE4 and CA125were 150pmol/L and 35U/ml,the sensitivity and specificity of HE4 for ovarian cancer diagnosis were 83.33% and95.12%.The sensitivity and specificity of CA125 were 69.04% and 78.05%,and those of ROMA were 85.71%and 95.12%,respectively.The AUC of ROC was 0.749（HE4）,0.676（CA125）and 0.814（ROMA）.The AUC of ROMA was higher than the others（P〈0.05）.Conclusion：The calculation of ROMA value may have better clinical value in the diagnosis of malignant ovarian tumors by HE4,CA125 level.
出处
《临床血液学杂志（输血与检验）》
CAS
2015年第3期475-477,共3页
Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
基金
湖北省自然科学基金资助项目(No:2012FFB02523)
关键词
人附睾分泌蛋白4
糖类抗原125
卵巢肿瘤风险预测模型
卵巢肿瘤
诊断
Human Epididymis Secretory Protein4
Cancer Antigen125
Risk of Ovarian Malignancy Algo-rithm
Ovarian cancer
diagnosis
